

Genetic variants in *PNPLA3* and *TM6SF2* predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis

Felix Stickel, MD, PhD¹, Stephan Buch, PhD², Hans Dieter Nischalke, PhD³, Karl Heinz Weiss, MD, PhD⁴, Daniel Gotthardt, MD, PhD⁴, Janett Fischer, PhD⁵, Jonas Rosendahl, MD, PhD⁶, Pierre Deltenre, MD⁷, Astrid Marot, MD⁷, Mona Elamly, MD⁷, Markus Casper, MD⁸, Frank Lammert, MD, PhD⁸, Andrew McQuillin, MD⁹, Steffen Zopf, MD¹⁰, Ulrich Spengler, MD, PhD³, Silke Marhenke, MD¹¹, Martha M. Kirstein, MD¹¹, Arndt Vogel, MD, PhD¹¹, Florian Eyer, MD, PhD¹², Johann von Felden, MD¹³, Henning Wege, MD¹³, Thorsten Buch, PhD¹⁴, Clemens Schafmayer, MD, PhD¹⁵, Felix Braun, MD¹⁵, Thomas Berg, MD, PhD⁵, Marsha Y. Morgan, MD, PhD¹⁶ and Jochen Hampe, MD, PhD²

- OBJECTIVES:** Variants in patatin-like phospholipase domain-containing 3 (*PNPLA3*; rs738409), transmembrane 6 superfamily member 2 (*TM6SF2*; rs58542926), and membrane bound O-acyltransferase domain containing 7 (*MBOAT7*; rs641738) are risk factors for the development of alcohol-related cirrhosis. Within this population, *PNPLA3* rs738409 is also an established risk factor for the development of hepatocellular carcinoma (HCC). The aim of this study was to explore possible risk associations of *TM6SF2* rs58542926 and *MBOAT7* rs641738 with HCC.
- METHODS:** Risk variants in *PNPLA3*, *TM6SF2*, and *MBOAT7* were genotyped in 751 cases with alcohol-related cirrhosis and HCC and in 1165 controls with alcohol-related cirrhosis without HCC. Association with the risk of developing HCC was analyzed using multivariate logistic regression.
- RESULTS:** The development of HCC was independently associated with *PNPLA3* rs738409 (OR_{adjusted} 1.84 [95% CI 1.55-2.18], $p = 1.85 \times 10^{-12}$) and *TM6SF2* rs58542926 (OR_{adjusted} 1.66 [1.30-2.13], $p = 5.13 \times 10^{-5}$), using an additive model, and controlling the sex, age, body mass index, and type 2 diabetes mellitus; the risk associated with carriage of *MBOAT7* rs641738 (OR_{adjusted} 1.04 [0.88-1.24], $p = 0.61$) was not significant. The population-attributable fractions were 43.5% for *PNPLA3* rs738409, 11.5% for *TM6SF2* rs58542926, and 49.9% for the carriage of both the variants combined.
- CONCLUSIONS:** Carriage of *TM6SF2* rs58542926 is an additional risk factor for the development of HCC in people with alcohol-related cirrhosis. Carriage of both *PNPLA3* rs738409 and *TM6SF2* rs58542926 accounts for half of the attributable risk for HCC in this population. Genotyping will allow for more precise HCC risk-stratification of patients with alcohol-related cirrhosis, and genotype-guided screening algorithms would optimize patient care.

SUPPLEMENTARY MATERIAL accompanies this paper at <https://doi.org/10.1038/s41395-018-0041-8>

Am J Gastroenterol <https://doi.org/10.1038/s41395-018-0041-8>

¹Department of Gastroenterology and Hepatology, University Hospital of Zurich, Zurich, Switzerland. ²Medical Department 1, University Hospital Dresden, TU Dresden, Dresden, Germany. ³Department of Internal Medicine I, University of Bonn, Bonn, Germany. ⁴Department of Internal Medicine IV, University Hospital Heidelberg, Heidelberg, Germany. ⁵Hepatology Section, Division of Gastroenterology and Rheumatology, University Hospital Leipzig, Leipzig, Germany. ⁶Department of Gastroenterology, University Hospital Halle/Saale, Halle, Germany. ⁷Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland. ⁸Department of Medicine II, Saarland University Medical Center, Homburg, Germany. ⁹Molecular Psychiatry Laboratory, Division of Psychiatry, University College London, London, UK. ¹⁰Medical Department 1, University of Erlangen, Nuremberg, Bavaria, Germany. ¹¹Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hanover, Germany. ¹²Department of Clinical Toxicology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany. ¹³First Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. ¹⁴Institute of Laboratory Animal Science, University of Zurich, Schlieren, Switzerland. ¹⁵Department of General and Thoracic Surgery, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. ¹⁶UCL Institute for Liver & Digestive Health, Division of Medicine, Royal Free Campus, University College London, London, United Kingdom. These authors have contributed equally to the presented work and share premier authorship: Felix Stickel, Stephan Buch. These authors have contributed equally to the presented work and share senior authorship: Pierre Deltenre, Thomas Berg, Marsha Y. Morgan, and Jochen Hampe. **Correspondence:** F.S. (email: Felix.stickel@uzh.ch)

Received 14 November 2017; revised 29 January 2018; accepted 18 February 2018

INTRODUCTION

The incidence of hepatocellular carcinoma (HCC) is increasing and it is now the fifth most frequent cancer and third most frequent cause of cancer-related mortality world-wide [1–3]. In western countries, the presence of cirrhosis is a major risk factor for the development of HCC, which only rarely evolves in non-cirrhotic livers [1, 4, 5]. Persistent high-alcohol consumption is the leading cause of cirrhosis in these areas. The prognosis of patients with HCC is grave as it is often detected only when it reaches an advanced stage.

Between 5 to 15% of patients with alcohol-related cirrhosis are potentially at risk for developing HCC with a 5-year cumulative risk of around 8% [1]. Identifying disease-modulating factors, which render some individuals more susceptible to its development than others, is clearly of major importance as it would allow more specific targeting of surveillance programmes. Older age, male sex, and more advanced liver disease at presentation are known to be important predictors, but do not account for more than a small proportion of the observed risk variance. Mounting evidence suggest that host genetic factors may significantly modify the risk for developing HCC. Thus, identifying these factors in patients with alcohol-related cirrhosis is clearly of major importance.

A single nucleotide polymorphism (SNP), rs738409 C > G, in patatin-like phospholipase domain-containing 3 (*PNPLA3*) is an established risk factor for the development of alcohol-related cirrhosis in Caucasian populations [6–9]. A recent meta-analysis of individual patient data from candidate gene studies has shown that the *PNPLA3* rs738409 G allele is also an independent risk factor for the development of HCC in this patient population [10, 11]. Recently, variants in two further genes viz. rs58542926 in transmembrane 6 superfamily member 2 (*TM6SF2*) and rs641738 in membrane bound O-acyltransferase domain containing 7 (*MBOAT7*) were identified as risk factors for the development of alcohol-related cirrhosis in a genome-wide association study (GWAS) [12]. Although a proportion of the cases included in the GWAS had developed HCC, the numbers were too small to allow a meaningful subset analysis. However, data from two candidate gene studies support a role for variants in or linked to *TM6SF2* as potential risk factors for HCC development. Thus, Nischalke et al. found a significant association between rs2228603, in the gene coding for neurocan (*NCAN*), and the development of HCC in people with alcohol-related cirrhosis [13]; this variant is in close linkage disequilibrium with *TM6SF2* rs58542926. Falletti et al. genotyped *TM6SF2* rs58542926 in 226 cases with alcohol-related cirrhosis, of whom 75 (33%) had HCC [14]. The rs58542926 T/*genotype was more frequent in those cases with HCC (adjusted odd ratio [OR] 2.57; $p = 0.035$). They found no interaction between *PNPLA3* rs738409 and *TM6SF2* rs58542926 and HCC risk. These preliminary findings need to be further explored. No studies have been undertaken, to date, to explore the possible risk association between *MBOAT7* rs641738 and the development of HCC in patients with alcohol-related cirrhosis.

The aim of the present study was to determine whether variants in *PNPLA3*, *TM6SF2*, and *MBOAT7* are the risk factors for the development of HCC, alone or in synergy, in a large, well-characterized population of people with alcohol-related cirrhosis.

METHODS

Patient cohorts

For purposes of this study, cases were defined as people with alcohol-related cirrhosis and HCC, and controls as people with alcohol-related cirrhosis but without evidence of HCC. Cases and controls were recruited from Hepatology centers across Europe (Switzerland, Germany, United Kingdom) and were of self-reported Swiss German/German/British/Irish ancestry (Supplementary Table 1).

The diagnosis of alcohol-related cirrhosis was established as described previously [12]; it was based on a history of prolonged, sustained alcohol intake of a minimum of 40 g/day in women and 60 g/day in men together with histological examination of liver tissue or compatible historical, clinical, laboratory, radiological, and endoscopic features. Patients were excluded if they had any other potential cause of liver injury, specifically if they were positive for hepatitis B surface antigen (HBsAg), anti-hepatitis C immunoglobulin G (anti-HCV IgG), anti-nuclear antibodies (ANA) (titer > 1:80), or anti-mitochondrial antibodies (titer > 1:40). Patients with elevated serum ferritin concentrations and a transferrin saturation of > 50% underwent high iron Fe (HFE) genotyping and were excluded if homozygous to the C282Y variant. Likewise, patients with a serum ceruloplasmin of < 20 mg/dl (0.2 g/dl) or serum alpha-1 antitrypsin of < 70 mg/dL (13 μ mol/L) were further investigated and excluded if necessary. Patients were also excluded if morbidly obese but not if overweight.

The diagnosis of HCC was based on histological examination of tumor tissue or evidence on imaging, preferably using two modalities of lesions that are hypervascular in the arterial phase with washout in the portal venous or delayed phases [15]. The severity of underlying alcohol-related liver injury was assessed using Pugh's modification of the Child's grading system [16].

DNA preparation and genotyping

DNA was prepared using the FlexiGene chemistry (Qiagen, Hilden, Germany). For preparation of genotyping, DNA samples were evaluated by gel electrophoresis and adjusted to 20–30 ng/ μ l DNA content using the Picogreen fluorescent dye (Molecular Probes – Invitrogen, Carlsbad, CA, USA) on a robotic platform with TECAN liquid-handling equipment. One microliter of genomic DNA was amplified with the GenomiPhi (Amersham, Uppsala, Sweden) whole-genome amplification kit and fragmented at 99 °C for 3 min. The 5 ng of DNA were dried overnight in TwinTec hardshell 384 well plates (Eppendorf, Hamburg, Germany) at room temperature. Genotyping of *PNPLA3* rs738409 (Assay ID HCV7241_10), *TM6SF2* rs58542926 (Assay ID HCV89463510_10), and *MBOAT7* rs641738 (Assay ID HCV8716820_10) was performed using TaqMan® SNP Genotyping Assays and chemistries (Applied Biosystems, Foster City, CA, USA) on an automated platform with TECAN Freedom EVO and 384 well TEMO liquid-handling robots (TECAN, Männedorf, Switzerland) as described before [12].

All process data were logged and administered with a database-driven LIMS. Reactions were completed and read in a 7900 HT TaqMan sequence detector system (Applied Biosystems, Foster City, CA, USA). The amplification reaction was carried out with

the TaqMan universal master mix. Thermal cycling conditions consisted of 1 cycle for 10 min at 95°C, followed by 45 cycles for 15 s at 95°C, and 45 cycles for 1 min at 60°C.

Statistical analysis

Statistical analysis of data were performed using SPSS v.24.0 (IBM Corp., Armonk, NY, USA). Comparisons of frequencies of genotypes at the three loci were performed on 3×2 contingency tables between the cases and the controls. Genotypic and allelic tests of association were performed using χ^2 statistics or Fisher's exact tests as appropriate. For all tests, nominal *p*-values are reported. The association between SNPs and the risk of HCC was estimated by calculating the beta coefficients and their standard errors using logistic regression models adjusted for age, sex, BMI, and diabetic status, assuming log-additive genetic effects. The interactions between polymorphic loci were examined by testing the allelic and the genotypic interaction terms in the logistic regression models. Results are expressed as odds ratios (OR) and 95% confidence intervals (CI).

Population-attributable fraction

The population-attributable fraction (PAF) provides an epidemiological estimate of the proportion with the disorder, which is attributable to the risk factor. Thus, it is an estimate of how much lower the frequency of HCC would be in the patients with alcohol-related cirrhosis, if the risk genotype(s) were eliminated from the population.

The PAF was estimated for heterozygous and homozygous carriage using the formula

$$(x-1)/x$$

where $x = (1-p)^2 + 2p(1-p)OR_1 + p^2OR_2$; *p* is the allele frequency in alcohol-related cirrhosis, and OR₁ and OR₂ are the ORs associated with hetero and homozygosity adjusted by sex, age, body mass index (BMI) and type 2 diabetes mellitus, respectively [17].

Combined PAF estimates were calculated based on the individual PAFs for each associated SNP, assuming no multiplicative interaction among the SNPs [17].

Ethics

The study was approved by the ethics committees of the participating institutions; all included subjects provided written informed consent prior to inclusion into the study.

RESULTS

The cases were significantly older than the controls; proportionately more were male, overweight and had comorbid type 2 diabetes mellitus (Table 1). However, the cases were significantly less likely to have decompensated liver disease (Table 1).

Genotyping was completed for all three SNPs with call-rates greater than 95%; there were significant differences in the genotyping call-rates between cases and controls, but the distributions of the missing data were random and not skewed. All markers

Table 1 Characteristics of cases and controls included in the study

Variable	Total (n=1916)	Cases (n=751)	Controls (n=1165)	Significance (<i>p</i>)
Proportion male (<i>n</i> : %)	1496 (78)	679 (90)	817 (70)	<0.00001
Age (yr)	58±11	61±10	55±10	<0.00001
BMI (kg/m ²)	26.6±4.7	27.9±4.7	25.9±4.6	<0.00001
BMI (%)				
<25	36%	26%	43%	
25–30	42%	42%	42%	
≥30	21%	32%	15%	<0.00001
Child Pugh Grade [16] (%)				
A	35%	48%	27%	
B	40%	36%	42%	
C	26%	16%	31%	<0.00001
Type II diabetes mellitus (<i>n</i> : %)	27 (1.4)	42 (5.6)	18 (1.5)	<0.00001
Data are reported as mean ± standard deviation or as number (%)				

followed Hardy–Weinberg equilibrium (cutoff HWE *P* > 0.05) in both the cases and the controls (Table 2).

Allelic and genotypic associations of *PNPLA3* rs738409 with HCC in alcohol-related cirrhosis were highly significant ($P_{\text{allelic}} = 3.64 \times 10^{-20}$, $P_{\text{genotypic}} = 6.14 \times 10^{-18}$). The odds ratio (OR) for homozygous carriers of the risk allele *PNPLA3* rs738409 G was 3.26 (95% CI: 2.50–4.25) compared to the risk in heterozygous carriers of 1.70 (95% CI: 1.37–2.10). The allelic and genotypic associations of *TM6SF2* rs58542926 with HCC in alcohol-related cirrhosis were also highly significant at $P_{\text{allelic}} = 8.93 \times 10^{-7}$ and $P_{\text{genotypic}} = 7.74371 \times 10^{-6}$, respectively. The OR for homozygous carriage of the risk allele *TM6SF2* rs58542926 T was 3.32 (95% CI: 1.76–6.24), while the OR for heterozygous carriage was 1.46 (95% CI: 1.15–1.84). In contrast, neither heterozygous nor homozygous carriage of the *MBOAT7* rs641738 T allele was associated with HCC risk; the allelic and genotypic levels of significance were $P_{\text{allelic}} = 0.639$ and $P_{\text{genotypic}} = 0.676$, respectively, while the corresponding ORs for homozygous and heterozygous carriage of the T allele were 1.07 (95% CI: 0.83–1.38) and 0.96 (95% CI: 0.77–1.20), respectively.

The minor allele frequencies (MAF) of all three loci in the controls in the present study were in line with those observed in the previous GWAS in alcohol-related cirrhosis [12], but the frequencies of *PNPLA3* rs738409 G and *TM6SF2* rs58542926 T were higher in the cases. The MAF for *MBOAT7* rs641738 T was similar in cases and controls.

The robustness of the association of *PNPLA3* rs738409, *TM6SF2* rs58542926 and development of HCC was confirmed after the adjustment for other known risk factors viz. age, sex, BMI and type 2 diabetes mellitus (Table 3). The lack of association with

Table 2 Genotypic and allelic frequencies of *PNPLA3*, *TM6SF2*, and *MBOAT7* in people with alcohol-related cirrhosis with HCC (cases) and without (controls)

SNP	Total (n = 1916)							Unadjust- ed OR (CI 95%)	Adjusted OR (CI 95%)	P trend	P _{allelic}	P _{genotypic}
<i>PNPLA3</i>		CC	CG	GG	MAF	fCG (%)	fGG (%)	CG vs. CC	GG vs. CC			
Cases	751	205	346	200	0.497	46%	27%	1.70 [1.37– 2.10]	3.26 [2.50– 4.25]	5.45E-19	3.64E-20	6.14E-18
Controls	1165	508	505	152	0.347	43%	13%					
<i>TM6SF2</i>		CC	CT	TT	MAF (%)	fCT (%)	fTT (%)	CT vs. TT	CC vs. TT			
Cases	751	558	164	29	0.148	22%	4%	1.46 [1.15– 1.84]	3.32 [1.76– 6.24]	1.22E-06	8.93E-07	7.74371E-06
Controls	1165	957	193	15	0.096	17%	1%					
<i>MBOAT7</i>		CC	CT	TT	MAF (%)	fCT (%)	fTT (%)	CT vs. TT	CC vs. TT			
Cases	751	203	363	185	0.488	48%	25%	0.96 [0.77– 1.20]	1.07 [0.83– 1.38]	0.377	0.639	0.676
Controls	1165	314	583	268	0.480	50%	23%					

MAF minor allele frequency, OR odds ratio

Table 3 Multivariate analysis of factors associated with hepatocellular carcinoma in people with alcohol-related cirrhosis

SNP	^a Adjusted OR (95% CI)	Significance (p)
<i>PNPLA3</i> rs738409:G	1.84 (1.55–2.18)	1.85×10^{-12}
<i>PNPLA3</i> rs738409:CG	2.07 (1.58–2.73)	1.87×10^{-07}
<i>PNPLA3</i> rs738409:GG	3.26 (2.31–4.60)	1.87×10^{-11}
<i>TM6SF2</i> rs58542926:T	1.66 (1.30–2.13)	5.13×10^{-05}
<i>TM6SF2</i> rs58542926:CT	1.67 (1.23–2.26)	1.03×10^{-03}
<i>TM6SF2</i> rs58542926:TT	2.86 (1.34–6.12)	6.75×10^{-03}
<i>MBOAT7</i> rs641738:T	1.04 (0.88–1.24)	0.61
<i>MBOAT7</i> rs641738:CT	0.90 (0.67–1.20)	0.473
<i>MBOAT7</i> rs641738:TT	1.09 (0.78–1.53)	0.619

SNP single nucleotide polymorphism, OR odds ratio, CI confidence interval
^a adjusted for age, gender, BMI, and type II diabetes mellitus.

MBOAT7 rs641738 did not change following adjustment for these confounders.

The association of *PNPLA3* rs738409 and *TM6SF2* rs58542926 with HCC was consistent across separate cohorts from Switzerland, Germany, Britain, and Ireland, as was the lack of association with regard to *MBOAT7* rs641738 (Supplementary Figures 1A–C).

The PAF% for *PNPLA3* rs738409 was 43.5% and for *TM6SF2* rs58542926 was 11.4%, yielding a combined PAF% for both risk loci of 49.9% (Table 4).

The proportion of cases and controls who carried either no, one out of two, or both risk variants in *PNPLA3* and *TM6SF2* illus-

Table 4 Population-attributable fraction of each variant with regard to the genetic risk of HCC in alcohol-related cirrhosis alone, and in combination

Genetic variant	^a Population-attributable fraction (%)
<i>PNPLA3</i> rs738409	43.5
<i>TM6SF2</i> rs58542926	11.5
<i>PNPLA3</i> + <i>TM6SF2</i> (combined)	49.9

^a Estimated for heterozygous and homozygous carriage in one equation.

trated the aggregated risk due to co-carriage of risk loci (Fig. 1). Thus, only 10% of the controls and approximately 20% of the cases carried both risk alleles.

DISCUSSION

Elucidating the genetic background of chronic liver diseases is important as it will enable an individual's risk to develop progressive liver damage to be assessed more precisely, and will allow greater insight into the currently unknown molecular aspects of the underlying pathophysiology. Of particular importance is the definition of the risk factors predisposing an individual with a priori cancer risk, i.e., cirrhosis, to the development of life-threatening malignancy, particularly if defining the risk factors would allow the development of a strategy for more individualized screening and targeted prevention.

The present study provides data of the largest cohort of patients with HCC and a background of alcohol-related cirrhosis under-




Fig. 1 Proportion of cases with alcohol-related cirrhosis and HCC by carriage of the risk variants in *PNPLA3* and *TM6SF2*

taken to date and provides further confirmation that the *PNPLA3* rs738409 G allele is the strongest independent genetic risk factor for HCC in this patient population [10, 11]. The present analysis further expands the panel of genetic risk factors for HCC to include *TM6SF2* rs58542926, albeit with lesser effect as reflected by its lower OR and PAF%. It also showed a lack of association with *MBOAT7* rs641738. There is only limited information on the possible risks associated with carriage of *TM6SF2* rs58542926 and *MBOAT7* rs641738 and the development of HCC, with which to compare the findings of the present study.

Nischalke et al. in a relatively small, multicentre study found a significant risk association between carriage of rs2228603 in *neurocan* (*NCAN*) and the development of HCC in patients with alcohol-related cirrhosis [13]. This genetic variant had been linked with the development of hepatic steatosis in a previous GWAS in non-alcoholic fatty liver disease (NAFLD) [18]. Subsequent genetic fine-mapping showed that *NCAN* rs2228603 lies within 50 kb and is in strong linkage disequilibrium with *TM6SF2* rs58542926 [19]. A subsequent exome-wide analysis conclusively identified *TM6SF2* rs58542926 as the more likely risk factor for progressive NAFLD in this genomic region [20]. Falletti et al. [14] analyzed a cohort of 511 patients with cirrhosis of mixed etiology, of whom 101 had HCC, and found an association between the risk of developing HCC and carriage of the *TM6SF2* rs58542926 T allele in the

226 patients with alcohol-related cirrhosis (Adjusted OR = 2.57; $p = 0.035$). They found no interaction between *PNPLA3* rs738409 and *TM6SF2* rs58542926 in relation to HCC risk.

A recent candidate gene-association study from Italy and the UK investigated the association between variants within *MBOAT7* and HCC in a mixed cohort of patients with NAFLD, chronic hepatitis C, and alcohol-related liver disease, the majority of whom did not have cirrhosis [21]. The authors reported a significant association between *MBOAT7* rs641738 and HCC in non-cirrhotic patients with NAFLD, but only in the Italian cohort. The findings were not however replicated in a validation cohort of UK patients. The reason for this discrepancy likely relates to the fact that development of HCC in non-cirrhotic patients and people with viral-related liver disease in western countries is very rare and hence the number of cases was small. Thus, the inability of these workers to replicate their findings may reflect the inconsistency of the chosen phenotypes studied and/or low statistical power.

The lack of association between HCC risk and *MBOAT7* rs641738 is further supported by a recent candidate gene study in people with chronic hepatitis C, which demonstrated that the influence of this variant is restricted to the transition from absence of fibrosis to mild fibrosis [22]. In this same study, no difference was observed in the MAF of *MBOAT7* rs641738 in a small subgroup of 75 people with HCV-related HCC within an entire cohort of 1706 indicating a lack of statistical power. However, the present study was adequately powered to detect an allelic odds ratio of 1.18 with 80% power, and hence the finding of no association between *MBOAT7* rs641738 and the development of HCC in alcohol-related cirrhosis is robust [23] and was consistent across all study subpopulation (Supplementary Figure 1C).

In the present study, carriage of risk alleles in *PNPLA3* and *TM6SF2* accounted for almost 50% of the population-attributable genetic risk for the development of HCC in patients with alcohol-related cirrhosis. The combined PAF% is usually lower than the sum of each individual PAR%, but not in this instance. The odds ratio was, in fact, greater than 3 for homozygous carriage and ~1.5 for heterozygous carriage for both variants, and hence surprisingly high for a germline genetic risk factor in a complex disorder.

The possibility that these genetic markers could be included in the stratification score to identify patients at high risk for HCC has to be considered. Hypothetically, screening intervals could be tailored according to the genetic signature in a given patient, applying longer intervals in those minimal inherited predisposition, and shorter periods for those who carry both risk alleles. However, any such proposals would need to be tested in prospective surveillance studies designed to assess the possible patient benefit.

Anstee et al. [24] have recently looked at the clinical utility of *PNPLA3* genotyping for stratifying the risk for developing HCC in patients with NAFLD in a reanalysis of the data published by Liu et al. [25]. They found that use of *PNPLA3* genotyping alone to positively predict the risk of developing HCC was unlikely to be tenable. However, the negative predictive value (NPV) was substantially greater, suggesting that genotyping this SNP

might have utility for selecting those individuals who are least likely to develop HCC and therefore, least likely to benefit from surveillance.

Using a similar approach, the diagnostic test performance for *PNPLA3* and *TM6SF2* genotyping for the detection of HCC

risk in the present study cohort showed a NPV of 72.5% for the combination *PNPLA3* rs738409 GG and *TM6SF2* rs58542926 *T. Based on these figures, a schema for individual screening intervals is proposed with the caveat that any adoption must be subjected to appropriate prospective evaluation (Table 5).

The distinct genetic profiles of the alcohol-related cirrhosis risk genes with regards to liver carcinogenesis also have intriguing functional implications. The *PNPLA3* rs738409 GG variant is considered a loss-of-function mutation, and as such is less able to hydrolyze triglycerides from lipid droplets leading to lipid trapping in hepatocytes and increased lipotoxicity. Since progression of fibrosis is only weakly associated with the degree of steatosis [26], additional effects beyond mere lipid accumulation are suspected. Thus, *PNPLA3* rs738409 has been functionally linked to increased levels of circulating pro-inflammatory mediator intra-cellular adhesion molecule 1 (ICAM-1) [27], which is also overexpressed in human HCC stem cells and circulating HCC tumor cells [28]. Furthermore, in patients with NAFLD *PNPLA3* rs738409 G allele was found to be associated with decreased levels of

Table 5 Proposed screening intervals for HCC of people with alcohol-related cirrhosis based on the genetic signature

Genetic background	Screening interval
<i>PNPLA3</i> rs738409 WT (CC), <i>TM6SF2</i> rs58542926:CC	24 months
<i>TM6SF2</i> rs58542926:T* and <i>PNPLA3</i> rs738409 CC	12 months
<i>TM6SF2</i> rs58542926:CC and <i>PNPLA3</i> rs738409 GG	6 months
<i>PNPLA3</i> rs738409 GG and <i>TM6SF2</i> rs58542926:T*	3 months




Fig. 2 Putative functions of proteins encoded by *PNPLA3*, *TM6SF2*, and *MBOAT7*. All proteins encoded by the three genes are enzymes related to lipid/fatty acid turnover are expressed in the liver tissue. The functional link to hepatocarcinogenesis is as yet unknown. **PNPLA3** [1] is an enzyme with both triacylglycerol lipase and acylglycerol O-acyltransferase activities and plays an important role in the balance of energy usage/storage in adipocytes, hepatocytes, and likely, hepatic stellate-cells [9, 34]. Expression of *PNPLA3* protein and mRNA increases the following food intake. The polymorphic variant (*PNPLA3* rs738409 G) is a loss-of-function mutation, in which structural alteration of the substrate-binding groove leads to lower substrate accessibility, and thus less triglyceride hydrolysis [35]. Also, the mutant variant rs738409 G, which locates on lipid droplets, evades proteasomal degradation by disrupting ubiquitylation [36]. Consequently, the mutant *PNPLA3* variant accumulates resulting in impaired triglyceride mobilization [36]. **TM6SF2** [2] is only incompletely characterized functionally, but appears to modulate hepatic lipoprotein export and lipidation of very low-density lipoproteins (VLDL). A functional link between *TM6SF2* and the microsomal triglyceride transfer protein (MTTP) jointly regulates the assembly and secretion of VLDL and triglycerides (TG) from liver cells into the bloodstream. The polymorphic variant of the *TM6SF2* gene (rs58542926 T) encodes a loss-of-function *TM6SF2* protein, which impairs VLDL export and, thus, increases intracellular lipids, but decreases the circulating serum VLDL, LDL, and triglyceride levels. These opposing functional differences result in distinct risk effects on steatosis and liver fibrosis (increased with variant rs58542926 T) [31] and on cardiovascular risk (increased with wild type rs58542926 C) [32]. **MBOAT7** [3] is a lysophosphatidylcholine acyltransferase, and as such is involved in membrane phospholipid remodeling. It catalyzes the transfer of acyl-CoA to lysophosphatidylcholine (LPI) with a strong propensity for arachidonoyl-CoA as the acyl donor [37]. Consequently, it may regulate the mechanisms by which pro-inflammatory free arachidonic acid (ArA) and eicosanoid levels are regulated. Increased availability of ArA leads to inflammatory signaling by prostaglandins and leukotrienes, which are potent chemoattractants of inflammatory cells. The *MBOAT7* rs641738 T allele leads to lower hepatic *MBOAT7* protein expression and changes in plasma phosphatidylcholine profiles consistent with a loss of function variation [38]

adiponectin, which has important anti-inflammatory, anti-fibrotic, and anti-carcinogenic properties [29]. Recent data in cell culture and mice xenografts also suggest an effect of *PNPLA3* rs738409 on the activation of the interleukin (IL)-6-Janus kinase (JAK2)/Signal Transducers and Activators of Transcription (STAT3) pathway via fatty acid-mediated inflammation [30]. Therefore, functional studies linking the 'lipid droplet disease', caused by *PNPLA3* malfunction, to cancer may likely unravel interesting insights into the pathophysiology of HCC.

While the promoting effect of *PNPLA3* rs738409 on HCC evolution remains incompletely understood, even less is known about the possible role of genetic variation of *TM6SF2* in this process. *TM6SF2* is involved in the assembly and secretion of very low-density lipoproteins, similar to microsomal triglyceride transfer protein (MTTP), and thus a loss-of-function mutation would be compatible with lipid accumulation in hepatocytes. Accordingly, Sookoian et al. [31] performed allele-specific expression analyses of cDNA isolated from liver tissue from patients with NASH and confirmed that the expression levels of the rs58542926 T allele are reduced to about 56% to that of the wild-type C allele. These findings suggest that carriage of the *TM6SF2* T risk allele is associated with decreased hepatic gene and protein expression, leading to a loss of function similar to the mutant *PNPLA3* variant. In turn, the wild-type *TM6SF2* protein has been associated with increased serum VLDL levels and an elevated cardiovascular risk [32], but less liver injury [33]. Whether and how there may be cross-talk between *TM6SF2* and signaling pathways pertinent for HCC development beyond mere intracellular lipid accumulation, lipotoxicity remains to be elucidated.

The putative functions of the three proteins: *PNPLA3*, *TM6SF2*, and *MBOAT7*, as well their polymorphic variants are illustrated in Fig. 2.

This study has its limitations, primarily the fact that it was undertaken retrospectively and was restricted to caucasian people with alcohol-related cirrhosis. Thus the findings do not necessarily define the genetic risks for HCC development in people with liver disease of other aetiologies or to other ethnic groups. However, it also has its strengths, including the size of the study population, and the fact that similar effect sizes were observed across component geographical cohorts. Thus, the presented data provides robust evidence for a strong effect of *PNPLA3* rs738409 on HCC risk in patients with alcohol-related cirrhosis. In addition, *TM6SF2* rs58542926 is identified and confirmed as a significant host genetic risk factor for HCC, while *MBOAT7* rs641738 is not. In combination, *PNPLA3* rs738409 and *TM6SF2* rs58542926 account for almost 50% of the population-attributable risk for the development of HCC, and thus, should be evaluated further for stratification of patients at risk in the screening programs. In addition, sight should not be lost of the fact that a significant proportion of the genetic variance still remains to be identified.

ACKNOWLEDGEMENTS

The authors thank the Clinical Research Support Service of the CHUV-UNIL, Lausanne, Switzerland for providing the infrastructure for patient recruitment and collecting phenotypic data.

CONFLICT OF INTEREST

Guarantor of the article: Dr. Felix Stickel, MD is accepting full responsibility for the conduct of the study. He had access to the data and has control of the decision to publish.

Specific author contributions: FS: conceived the study, raised the pivotal funding, contributed biological material from cases and controls, analyzed the data, wrote the manuscript, acted as the corresponding author and approved the final draft submitted. SB: analyzed the primary data, performed the biostatistics, critically revised the manuscript and approved the final draft submitted. HDN: contributed biological material from phenotyped cases and controls, critically revised the manuscript and approved the final draft submitted. KHW: contributed biological material from phenotyped cases and controls, critically revised the manuscript and approved the final draft submitted. DG: contributed biological material from phenotyped cases and controls, critically revised the manuscript and approved the final draft submitted. JF: contributed biological material from phenotyped cases and controls, critically revised the manuscript and approved the final draft submitted. JR: contributed biological material from phenotyped cases and controls, critically revised the manuscript and approved the final draft submitted. PD: contributed biological material from phenotyped cases and controls, critically revised the manuscript and approved the final draft submitted. AM: recruited and phenotyped patients, contributed biological material from phenotyped cases and controls, critically revised the manuscript and approved the final draft submitted. ME: recruited and phenotyped patients, contributed biological material from phenotyped cases and controls, critically revised the manuscript and approved the final draft submitted. MC: recruited and phenotyped patients, contributed biological material from phenotyped cases and controls, critically revised the manuscript and approved the final draft submitted. FL: phenotyped patients, contributed biological material from phenotyped cases and controls, critically revised the manuscript and approved the final draft submitted. AM: reanalyzed the data for biostatistical issues, critically revised the manuscript and approved the final draft submitted. SZ: phenotyped patients, contributed biological material from phenotyped cases and controls, critically revised the manuscript and approved the final draft submitted. US: raised local funding for genetic studies in Bonn, critically revised the manuscript and approved the final draft submitted. SM: contributed biological material from phenotyped cases and controls, critically revised the manuscript and approved the final draft submitted. MK: contributed biological material from phenotyped cases and controls, critically revised the manuscript and approved the final draft submitted. AV: contributed biological material from phenotyped cases and controls, critically revised the manuscript and approved the final draft submitted. FE: conceived the study design, was instrumental for the network build-up, contributed biological material from phenotyped cases and controls, critically revised the manuscript and approved the final draft submitted. JVF: recruited cases and controls prospectively, contributed biological material from phenotyped cases and controls, critically revised the manuscript and approved the final draft submitted. HW: contributed biological material from phenotyped cases and controls, critically

revised the manuscript and approved the final draft submitted. TB: raised study funding, critically revised the genetic study protocol, revised the manuscript and approved the final draft submitted. CS: recruited cases and controls prospectively, contributed biological material from phenotyped cases and controls, critically revised the manuscript and approved the final draft submitted. FB: recruited cases and controls prospectively, contributed biological material from phenotyped cases and controls, and approved the final draft submitted. TB: conceived the study design, was instrumental for the network build-up, contributed biological material from phenotyped cases and controls, critically revised the manuscript and approved the final draft submitted. MYM: conceived the study design, was instrumental for the network build-up, contributed biological material from phenotyped cases and controls, interpreted the data, wrote the paper, and approved the final draft submitted. JH: conceived the study design, was instrumental for the network build-up, analyzed and interpreted the data, contributed biological material from phenotyped cases and controls, wrote the paper, and approved the final draft submitted.

Financial support: This work was supported by grants from the Swiss National Funds (SNF no. 310030_169196) and the Swiss Foundation for Alcohol Research (SSA) to FS and TB. This project was also supported by the Liver Systems Medicine, the ERACoSysMed project DYNAFLOW and EPITrio through the German Ministry for Research and Education (BmBF) to JH. HDN and US were supported by a grant from the Deutsche Krebshilfe (70112169).

Potential competing interests: None.

Study Highlights

WHAT IS CURRENT KNOWLEDGE

- ✓ The gene variant *PNPLA3* rs738409 is an established risk factor for the development of alcohol-related cirrhosis and for the subsequent development of hepatocellular carcinoma (HCC) within this population.
- ✓ Two other risk variants, *TM6SF2* rs58542926 and *MBOAT7* rs641738, are associated with the development of alcohol-related cirrhosis, but their role in the subsequent development of HCC is unclear.

WHAT IS NEW HERE

- ✓ While *PNPLA3* rs738409 is confirmed as a risk factor for HCC in alcoholic cirrhotics, the present study identifies *TM6SF2* rs58542926 as an independent risk factor for the development of HCC in people with alcohol-related cirrhosis.
- ✓ The dual carriage of these risk variants in *PNPLA3* and *TM6SF2* accounts for almost 50% of the attributable risk for the development of HCC in this population.
- ✓ In contrast to its role as a risk factor for alcoholic cirrhosis, *MBOAT7* rs641738 does not seem to confer risk to HCC development in this risk group.
- ✓ Genotype-based risk stratification for patients with alcohol-related cirrhosis may guide the development of rational, cost-effective surveillance programmes to facilitate early HCC detection.

REFERENCES

1. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. *Gastroenterology*. 2004;127:S35–50.
2. McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. *Clin Liver Dis*. 2011;15:223–43.
3. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. *Dig Liver Dis*. 2010;42(Suppl. 3):S206–14.
4. Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. *Hepatology*. 2010;51:1972–8.
5. Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. *Nat Rev Cancer*. 2007;7:599–612.
6. Stickel F, Moreno C, Hampe J, Morgan MY. Genetics of alcohol dependence and alcohol-related liver disease. *J Hepatol*. 2017;66:195–211.
7. Chamorro AJ, Torres JL, Miron-Canelo JA, et al. Systematic review with meta-analysis: the I148M variant of patatin-like phospholipase domain-containing 3 gene (*PNPLA3*) is significantly associated with alcoholic liver cirrhosis. *Aliment Pharmacol Ther*. 2014;40:571–81.
8. Stickel F, Buch S, Lau K, et al. Genetic variation in the *PNPLA3* gene is associated with alcoholic liver injury in Caucasians. *Hepatology*. 2011;53:86–95.
9. Stickel F, Hampe J, Trepo E, et al. *PNPLA3* genetic variation in alcoholic steatosis and liver disease progression. *Hepatobiliary Surg Nutr*. 2015;4:152–60.
10. Singal AG, Manjunath H, Yopp AC, et al. The effect of *PNPLA3* on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. *Am J Gastroenterol*. 2014;109:325–34.
11. Trepo E, Nahon P, Bontempi G, et al. Association between the *PNPLA3* (rs738409 C>G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data. *Hepatology*. 2014;59:2170–7.
12. Buch S, Stickel F, Trepo E, et al. A genome-wide association study confirms *PNPLA3* and identifies *TM6SF2* and *MBOAT7* as risk loci for alcohol-related cirrhosis. *Nat Genet*. 2015;47:1443–8.
13. Nischalke HD, Lutz P, Kramer B, et al. A common polymorphism in the *NCAN* gene is associated with hepatocellular carcinoma in alcoholic liver disease. *J Hepatol*. 2014;61:1073–9.
14. Falletti E, Cussigh A, Cmet S, et al. *PNPLA3* rs738409 and *TM6SF2* rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosis. *Dig Liver Dis*. 2016;48:69–75.
15. EASL–EORTC. Clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol*. 2012;56:908–43.
16. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. *Br J Surg*. 1973;60:646–9.
17. Tomlinson IP, Webb E, Carvajal-Carmona L, et al. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. *Nat Genet*. 2008;40:623–30.
18. Speliotes EK, Yerges-Armstrong LM, Wu J, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. *PLOS Genet*. 2011;7:e1001324.
19. Liu YL, Reeves HL, Burt AD, et al. *TM6SF2* rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. *Nat Commun*. 2014;5:4309.
20. Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a *TM6SF2* variant that confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet*. 2014;46:352–6.
21. Donati B, Dongiovanni P, Romeo S, et al. *MBOAT7* rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. *Sci Rep*. 2017;7:4492.
22. Thabet K, Asimakopoulos A, Shojaei M, et al. *MBOAT7* rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. *Nat Commun*. 2016;7:12757.
23. Dupont WD, Plummer WD. Power and sample size calculations for studies involving linear regression. *Control Clin Trials*. 1998;19:589–601.
24. Anstee QM, Liu YL, Day CP, Reeves HL. Reply to: HCC and liver disease risk in homozygous *PNPLA3*p.I148M carriers approach monogenic inheritance. *J Hepatol*. 2015;62:982–3.
25. Liu YL, Patman GL, Leathart JB, et al. Carriage of the *PNPLA3*rs738409 C>G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. *J Hepatol*. 2014;61:75–81.
26. Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver

- fibrosis in patients with nonalcoholic fatty liver disease. *Hepatology*. 2010;51:1209–17.
27. Pare G, Ridker PM, Rose L, et al. Genome-wide association analysis of soluble ICAM-1 concentration reveals novel associations at the *NFKB1K*, *PNPLA3*, *RELA*, and *SH2B3* loci. *PLOS Genet*. 2011;7:e1001374.
 28. Liu S, Li N, Yu X, et al. Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells. *Gastroenterology*. 2013;144:1031–41.
 29. Valenti L, Rametta R, Ruscica M, et al. The I148M *PNPLA3* polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. *BMC Gastroenterol*. 2012;12:111.
 30. Liu Z, Chen T, Lu X, et al. Overexpression of variant *PNPLA3* gene at I148M position causes malignant transformation of hepatocytes via IL-6-JAK2/STAT3 pathway in low dose free fatty acid exposure: a laboratory investigation in vitro and in vivo. *Am J Transl Res*. 2016;8:1319–38.
 31. Sookoian S, Castaño GO, Scian R, et al. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. *Hepatology*. 2015;61:515–25.
 32. Holmen OL, Zhang H, Fan Y, et al. Systematic evaluation of coding variation identifies a candidate causal variant in *TM6SF2* influencing total cholesterol and myocardial infarction risk. *Nat Genet*. 2014;46:345–51.
 33. Sookoian S, Pirola CJ. Meta-analysis of the influence of *TM6SF2 E167K* variant on plasma concentration of aminotransferases across different populations and diverse liver phenotypes. *Sci Rep*. 2016;6:27718.
 34. Bruschi FV, Claudel T, Tardelli M, et al. The *PNPLA3* I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells. *Hepatology*. 2017;65:1875–90.
 35. He S, McPhaul C, Li JZ, et al. A sequence variation (I148M) in *PNPLA3* associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. *J Biol Chem*. 2010;285:670–15.
 36. BasuRay S, Smagris E, Cohen JC, et al. The *PNPLA3* variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation. *Hepatology*. 2017;66:1111–24.
 37. Gijón MA, Riekhof WR, Zarini S, et al. Lysophospholipid acyltransferases and arachidonate recycling in human neutrophils. *Biol Chem*. 2008;283:30235–45.
 38. Mancina RM, Dongiovanni P, Petta S, et al. The *MBOAT7-TMC4* variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. *Gastroenterology*. 2016;150:1219–30.